Results of antiviral therapy of viral respiratory infection in selected groups of patients

Ruzhentsova T.A., Garbuzov A.A., Kanibolotskiy A.A., Borisova O.Y., Voropaeva E.A., Khavkina D.A., Khalyastov I.N., Orlova V.A., Mikhailova I.I., Kaluzhnaya N.O.

Gabrichevsky Research Institute for Epidemiology and Microbiology, Moscow, Russia
Moscow Medical University "Reaviz", Moscow, Russia
N.V. Sklifosovsky Research Institute for Emergency Medicine, Moscow, Russia
Rehabilitation Center of the Pension and Social Insurance Fund of the Russian Federation "Volginsky", Russia
Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

The aim is to substantiate the need and evaluate the effectiveness of inosine pranobex therapy for viral respiratory infections in patients with psychiatric pathology.
Materials and methods. At stage 1, 59 patients with a background of manifestations of schizophrenia or schizotypal disorder were included in the retrospective study, in whom repeated viral respiratory infection was observed. The main group included 27 patients who received inosine pranobex (Groprinosin), and in the comparison group 32 patients were treated for viral respiratory infections with other drugs. At stage 2, 210 tissue samples of deceased patients with parkinsonism (15), schizophrenia or hallucinosis (15) or in the absence of these pathologies (12) were examined for the presence of herpes viruses.
Results. In the group treated with inosine pranobex, the period of viral respiratory infection was 6.3±1.63, and with other therapy – 7.8±2.78 days. Complications in the main group were noted in 7%, and in the comparison group – in 28%. Inosine pranobex therapy was accompanied by an improvement in the course of psychiatric pathology. Viruses were most often detected in patients with schizophrenia and hallucinosis: HHV-6 DNA in 29 samples (39%) obtained from13 patients (87%), cytomegalovirus (CMV) DNA in 7 (47%) patients in 11 samples (15%), Epstein-Barr virus (EBV) in 5 patients (33%) in 10 samples (13%), more often in kidney samples.
Conclusions. Inosine pranobex (Groprinosine) reduces the course of viral respiratory infections by 1.5 days, reduces the frequency of complications by 4 times, reduces the frequency of repeated episodes of viral respiratory infections by 3 times, reduces the frequency and severity of relapses of schizophrenia and schizotypal disorders. The necessity to use an effective antiviral and immunomodulatory drug is confirmed by more frequent detection of HHV-6 and CMV DNA in organs, more often in the kidneys, in patients with schizophrenia and hallucinosis.